Caricamento...
Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials
INTRODUCTION: Interleukin-17 inhibitors are the newest class of monoclonal antibodies approved by the US Food and Drug Administration for the treatment of psoriasis. Preclinical and Phase II studies of ixekizumab, a high-affinity anti-IL-17A monoclonal antibody, have proved promising. METHODS: We co...
Salvato in:
| Pubblicato in: | Dermatol Ther (Heidelb) |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Healthcare
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4799032/ https://ncbi.nlm.nih.gov/pubmed/26910853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-016-0102-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|